EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Urine Extracellular Vesicle miRNA Changes Induced by Vicadrostat with/Without Empagliflozin in Patients with Chronic Kidney Disease

Denis Delic iD, Isabella Gashaw iD, Ileana Duran-Fernandez, Lisa Cronin, Sibylle J Hauske, Peter Rossing, Katherine R Tuttle iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262210810 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Denis Delic und 6 weiteren Autor:innen. Beteiligte Einrichtung: Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach, Germany. Hauptthemen laut MEDLINE: MicroRNAs, Benzhydryl Compounds, Glucosides, Extracellular Vesicles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vicadrostat, a selective aldosterone synthase inhibitor, reduced albuminuria with concurrent renin–angiotensin system inhibition and empagliflozin, suggesting additive efficacy for chronic kidney disease (CKD) treatment. Specific urinary extracellular vesicle microRNAs (uEV miRNAs) may reflect key mechanisms of kidney injury. We investigated how vicadrostat alone or with empagliflozin affected uEV miRNA expression in study participants. Small RNA sequencing was conducted on uEV miRNAs from 435 participants with CKD who completed 14 weeks treatment in the phase II trial of vicadrostat given with or without empagliflozin. Differentially expressed uEV miRNAs in participants with ≥30% UACR (urine albumin–creatinine ratio) reduction treated with 10 or 20 mg vicadrostat were pooled and evaluated with or without empagliflozin. Changes in miRNA-142-5p correlated significantly with changes in UACR in participants treated with vicadrostat alone, whereas changes in expression of eight additional uEV miRNAs (miR-192-5p, miR-194-5p, miR-6882-5p, miR-27a-5p, miR-381-3p, miR-192-3p, miR-513a-5p, and miR-199b-3p) correlated with ≥30% UACR improvements in patients treated with vicadrostat plus empagliflozin. Cellular deconvolution revealed that these miRNAs were expressed in various kidney cell types. Vicadrostat plus empagliflozin altered uEV miRNAs involved in immunomodulatory and fibrotic pathways irrespective of participant diabetes status. Regulation of miRNAs may provide insights into synergistic mechanisms of vicadrostat and empagliflozin in CKD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsBenzhydryl CompoundsGlucosidesExtracellular VesiclesRenal Insufficiency, ChronicHumansMaleFemaleMiddle AgedAgedSodium-Glucose Transporter 2 Inhibitors

Stichwörter der Autor:innen

SGLT2 inhibitionalbuminuriaaldosterone synthase inhibitionbiomarkersdiabetes

Substanzen

MicroRNAsBenzhydryl CompoundsGlucosidesempagliflozinSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach, Germany.
  • Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology), University Medical Centre Mannheim, University of Heidelberg, 68167 Heidelberg, Germany.
  • Boehringer Ingelheim Pharma GmbH & Co. KG, 55216 Ingelheim am Rhein, Germany.
  • Staburo GmbH, 81549 Munich, Germany.
  • Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT 06877, USA.
  • Boehringer Ingelheim International GmbH, 55216 Ingelheim am Rhein, Germany.

ORCID-Profile: Denis Delic, Isabella Gashaw, Katherine R Tuttle

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Delic, D., Gashaw, I., Duran-Fernandez, I., Cronin, L., Hauske, S. J., Rossing, P., & Tuttle, K. R. (2025). Urine Extracellular Vesicle miRNA Changes Induced by Vicadrostat with/Without Empagliflozin in Patients with Chronic Kidney Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262210810

Vancouver

Delic D, Gashaw I, Duran-Fernandez I, Cronin L, Hauske SJ, Rossing P, et al. Urine Extracellular Vesicle miRNA Changes Induced by Vicadrostat with/Without Empagliflozin in Patients with Chronic Kidney Disease. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262210810

BibTeX
@article{Delic2025,
  author = {Delic, Denis and Gashaw, Isabella and Duran-Fernandez, Ileana and Cronin, Lisa and Hauske, Sibylle J and Rossing, Peter and Tuttle, Katherine R},
  title = {Urine Extracellular Vesicle miRNA Changes Induced by Vicadrostat with/Without Empagliflozin in Patients with Chronic Kidney Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262210810}
}
Kostenlos starten →